August 2023
Vol 9 | Issue 602

Q&A with Rene Anand of Neurxstem Inc.

CEO & Founder

Principal Series:

Neurxstem Inc. is a US-based, predictive and precision genomic medicine company dedicated to finding innovative solutions to the most challenging human brain diseases.

Neurxstem has patented a novel, first-in-class Neural Organoid Platform that closely mimics the human central nervous system. This produces a patented drug discovery technology that is based on brain organoids derived from human stem cells. This technology is unique in that it allows us to study the brain genome in a way that was previously impossible, providing a huge step forward in our understanding of debilitating diseases such as Alzheimer’s, brain cancer, Autism, and Parkinson’s.



NeurXstem’s CEO is excited to be invited to another major global conference on Alzheimer’s disease in Lausanne, Switzerland, Oct. 10-12th.

The other one is the Longevity Investors Conference in Gstaad, just a few weeks before! Delighted to share that NeurXstem is only one of 8 Startup Top Innovators selected to showcase at this highly exclusive ‘Longevity Investors Conference’ in Gstaad, Switzerland, on Sept. 27-28th, 2023!

“CEOi Convener and Davos Alzheimer’s Collaborative (DAC) Founder, George Vradenburg’s, recent opinion editorial article in the global health newsletter of the Council on Foreign Relations, The Cost of Inaction. In the article, Lausanne X sponsor DAC calls on governments around the world to step up efforts to invest in Alzheimer’s.”

“The time is long overdue for governments worldwide to respond to — and budget for — Alzheimer’s as the serious public health crisis that it is.”

Top Innovator Pitch at a SilVal event, May10th-11th, “EmergingTechVentures” – a very big VC only event in CA.

Top Innovator Pitch at ‘TechConnectWorld’ event in DC June 19th-21st. This one is a VC pitch and the second 20-minute science presentation on precision health symposium at the same event.

Top Innovator Pitch at 2023 BioPartnering Conference, April 18th.
Sponsored by JP Morgan, J&J Innovation, and Morgan Lewis
Big Pharma looking for drugs for cures.

Neurxstem selected as an Innovator Showcase Presenter at the ADDF Aging symposium on April 13th, in Berkeley!
Pitch Presentations from 10 Selected Companies: Introduction

This technology is unique in that it allows us to study the brain genome in a way that was previously impossible, providing a huge step forward in our understanding of debilitating diseases such as Alzheimer’s, Aging, brain cancer, Autism, and Parkinson’.

Top Innovator show-case at Longevity Investors Conference, Gstaad, Switzerland, Sept 27th-28th, 2023.
Longevity Investors Conference



Join us for Family Office Insights Luminary Series Interview followed by Family Office Insights 1 hour Virtual Pitch Webinar featuring Dr. Rene Anand, entrepreneur, and CEO & Founder of Neurxstem, Inc., an Avant-garde precision and predictive genomic brain medicine company developing early diagnostics and therapeutics for debilitating brain disease and disorders, including Alzheimer’s, Parkinson’s, autism, PTSD, Pain, and Brain Cancer and Aging (progeria).

Aug 22, 2023 at 2:15pm-3:15pm EST
RSVP & Confirmation Required
Investors Only Please!

Family Office Insights is a voluntary, “opt-in” collaborative peer-to-peer community of single family offices, qualified investors and institutional investors. Join the community here

What makes human brain models so important for finding cures for brain diseases and diorders?

Mouse models, the standard 'status quo' for decades have been very misleading and caused repeated failure of big Pharma to bring to market effective cures. The financial loss has been for investors and the government >$100B

How do you know your stem cell brain models for Alzheimer's disease is correctly reflecting AD etiology?

We know this because the hundreds of genes dysregulated in our AD models compared to those from normal donor models match those of both AD patient postmortem brains as well as those of recent genetic studies from AD patients.

Do you have promising drugs for Alzheimer's that dont target the gravestone markers of AD - amyloid plaques and tau fibrils? If so how do you know they are 'promising' in pre-clinical testing with the AD models as part of your journey to IND enabling studies for FDA approval and clinical trials? Are any of them already FDA approved and repurposed drugs, that can be brought to market rapidly after a Phase 2 trial?

We have used the big data from our models to do data analytics to find the likely early causes of AD and once we found them, we then tested drugs against them. They are 'promising' because they reverse the changes in gene expression of differences between AD and normal human brain models. The reversal is for hundreds of upstream genes and early genes that are drivers of AD pathology and eventually cognitive failure as we age.

Rene Anand of Neurxstem Inc.

Contact Rene: